PBAC plan to restrict diabetes drug prescribing ‘inconsistent with guidelines’

Associate Professor Neale Cohen also criticised the PBAC for rejecting a potential PBS listing for tirzepatide.
Associate Professor Neale Cohen.

A proposed PBS crackdown on GLP-1 receptor agonists is inconsistent with type 2 diabetes management guidelines and will force doctors to prescribe less efficacious drugs, says a leading endocrinologist.

Following its July meeting, the PBAC has said subsidies for dulaglutide and semaglutide should be restricted to patients with contraindications, intolerance or inadequate response to SGLT-2 inhibitor therapy.